Targeted therapy for advanced esophagogastric adenocarcinoma

Critical Reviews in Oncology/Hematology

Volumn 90, Issue 1, 2014, Pages 68-76

  Kordes, S ^a   Cats, A ^b   Meijer, S L ^a   Van Laarhoven, H W M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

C MET; EGFR; Esophageal cancer; Gastric cancer; HER2; MTOR; Targeted therapy; VEGFR

Indexed keywords

ANTINEOPLASTIC AGENT; APATINIB; BEVACIZUMAB; CAPECITABINE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROPYRIMIDINE; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; OXALIPLATIN; PERTUZUMAB; PLACEBO; RAMUCIRUMAB; SCATTER FACTOR RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADVANCED CANCER; ARTERIAL THROMBOEMBOLISM; BLEEDING; BREAST CANCER; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL EFFECTIVENESS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOGASTRIC ADENOCARCINOMA; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERTENSION; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN TARGETING; PROTEINURIA; REVIEW; SKIN TOXICITY; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH CARCINOMA; STOMACH PERFORATION; SURVIVAL TIME; TUMOR VASCULARIZATION; UPREGULATION;

C-MET; EGFR; ESOPHAGEAL CANCER; GASTRIC CANCER; HER2; MTOR; TARGETED THERAPY; VEGFR;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; ESOPHAGEAL NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; STOMACH NEOPLASMS;

EID: 84895431267     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.10.004     Document Type: Review

References (62)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90. March.
2. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917. December.
3. Cunningham D., Okines A.F., Ashley S. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2010, 362(9):858-859. March.
4. Bang Y.J., Van C.E., Feyereislova A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 9742(376):687-697. August.
5. Marsman W.A., Tytgat G.N., ten Kate F.J., van Lanschot J.J. Differences and similarities of adenocarcinomas of the esophagus and esophagogastric junction. J Surg Oncol 2005, 92(3):160-168. December.
6. Cappetta A., Lonardi S., Pastorelli D., Bergamo F., Lombardi G., Zagonel V. Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies. Crit Rev Oncol Hematol 2012 Jan, 81(1):38-48.
7. Fornaro L., Lucchesi M., Caparello C., et al. Anti-HER agents in gastric cancer: from bench to bedside. Nat Rev Gastroenterol Hepatol 2011, 8(7):369-383. July.
8. Ross J.S., McKenna B.J. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001, 19(5):554-568.
9. Chan D.S., Twine C.P., Lewis W.G. Systematic review and meta-analysis of the influence of HER2 expression and amplification in operable oesophageal cancer. J Gastrointest Surg 2012, 16(10):1821-1829. October.
10. Pazo Cid R.A., Anton A. Advanced HER2-positive gastric cancer: current and future targeted therapies. Crit Rev Oncol Hematol 2013, 85(3):350-362. March.
11. Liu Y.H., Xu F.P., Rao J.Y., et al. Justification of the change from 10% to 30% for the immunohistochemical HER2 Scoring criterion in breast cancer. Am J Clin Pathol 2009, 132(1):74-79. July.
12. Wolff A.C., Hammond M.E., Schwartz J.N., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007, 131(1):18-43.
13. Hofmann M., Stoss O., Shi D., et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008, 52(7):797-805. June.
14. Prins M.J., Ruurda J.P., van Diest P.J., van H.R., ten Kate F.J. The significance of the HER-2 status in esophageal adenocarcinoma for survival: an immunohistochemical and an in situ hybridization study. Ann Oncol 2013, 24(5):1290-1297. May.
15. Yoon H.H., Shi Q., Sukov W.R., et al. HER2 testing in esophageal adenocarcinoma (EAC) using parallel tissue-based methods. J Clin Oncol 2012, 30(Suppl. (34)). abstr 2.
16. Tapia C., Glatz K., Novotny H., et al. Close association between HER-2 amplification and overexpression in human tumors of non-breast origin. Mod Pathol 2007, 20(2):192-198. February.
17. Hudis C.A. Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med 2007, 357(1):39-51. July.
18. Arteaga C.L., Sliwkowski M.X., Osborne C.K., Perez E.A., Puglisi F., Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2012, 9(1):16-32. January.
19. Hoffman-La Roche A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction or Gastric Cancer. ClinicalTrials gov [Internet] 2013, National Library of Medicine (US), Bethesda (MD), March. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01774786.
20. Agus D.B., Akita R.W., Fox W.D., et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002, 2(2):127-137. August.
21. Swain S.M., Kim S.B., Cortes J., et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013, 14(6):461-471. May.
22. Blackwell K., Miles D., Bianchi G.V., et al. Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. J Clin Oncol 2012, 30(Suppl. (27)). abstr LBA1.
23. Hoffmann-La Roche A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer (NCT01641939). NL 2013 2013, June. Available from: http://www.clinicaltrials.gov.
24. Hecht J., Urba S., Koehler M., et al. Lapatinib monotherapy in recurrent upper gastrointestinal malignancy: phase II efficacy and biomarker analyses. Proceedings ASCO 2008 Gastrointestinal Cancers Symposium 2008.
25. Iqbal S., Goldman B., Fenoglio-Preiser C.M., et al. Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Ann Oncol 2011, 22(12):2610-2615. December.
26. Hecht J., Bang Y.J., Qin S., Chung H.C., Xu J., Park J.O. Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): the TRIO-013/LOGiC Trial. J Clin Oncol 2013, 31(Suppl. (l)). abstr LBA4001.
27. Ford H., Marshall A., Wadsley J., et al. COUGAR-02: a randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma. ASCO Meet Abstr 2013, 31(Suppl. (4)):LBA4.
28. Kang J.H., Lee S.I., Lim d.H., et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 2012, 30(13):1513-1518. May.
29. Bang Y.J. A randomized, open-label, phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone in the second-line treatment of HER2 amplified advanced gastric cancer (AGC) in Asian population: Tytan study. J Clin Oncol 2013, 30(Suppl. (34)). abstr 11.
30. Modjtahedi H., Essapen S. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs 2009, 20(10):851-855. November.
31. Ku G.Y., Ilson D.H. Esophagogastric cancer: targeted agents. Cancer Treat Rev 2010, 36(3):235-248. May.
32. Burtness B., Hollis D., Niedzwiecki D., et al. CALGB 80403/ECOG 1206: a randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. J Clin Oncol 2010, 28(15s). abstr 4006.
33. Pinto C., Di F.F., Siena S., et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 2007, 18(3):510-517. March.
34. Yeh K., Hsu C., Lin C., et al. Phase II study of cetuximab plus weekly cisplatin and 24-hour infusion of high-dose 5-fluorouracil and leucovorin for the first-line treatment of advanced gastric cancer. J Clin Oncol 2009, 20(27):15S. May.
35. Lordick F., Kang Y.K., Chung H.C., et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 2013, 14(6):490-499. May.
36. Waddell T.S., Chau I., Barbachano Y., et al. A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3). ASCO Meet Abstr 2012, 30(Suppl. (18)):LBA4000. June.
37. Hwang M., Shin K. Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer. ClinicalTrials gov [Internet] 2013, National Library of Medicine (US), Bethesda (MD), March. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01813253.
38. Prins M.J., Verhage R.J., ten Kate F.J., van H.R. Cyclooxygenase isoenzyme-2 and vascular endothelial growth factor are associated with poor prognosis in esophageal adenocarcinoma. J Gastrointest Surg 2012, 16(5):956-966. May.
39. Zagouri F., Papadimitriou C.A., Dimopoulos M.A., Pectasides D. Molecularly targeted therapies in unresectable-metastatic gastric cancer: a systematic review. Cancer Treat Rev 2011, 37(8):599-610. December.
40. Ohtsu A., Shah M.A., Van C.E., et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011, 29(30):3968-3976. October.
41. Shah M.A., Ramanathan R.K., Ilson D.H., et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006, 24(33):5201-5206. November.
42. Shah M.A., Jhawer M., Ilson D.H., et al. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol 2011, 29(7):868-874. March.
43. Shah M.A., Van Cutsem E., Kang Y.K., et al. Survival analysis according to disease subtype in AVAGAST: first-line capecitabine and cisplatin plus bevacizumab (bev) or placebo in patients (pts) with advanced gastric cancer. ASCO Meet Abstr 2012, 30(Suppl. (4)):5. January.
44. Van Cutsem E., de Haas S., Kang Y.K., et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 2012, 30(17):2119-2127. June.
45. Fuchs C.S., Tomasek J., Cho J.Y., et al. REGARD: a phase III, randomized, double-blinded trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing combination therapy. ASCO Meet Abstr 2013, 31(Suppl. (4)):LBA5. January.
46. ImClone L.L.C. A Study of Paclitaxel with or without Ramucirumab in Metastatic Gastric Adenocarcinoma (RAINBOW). ClinicalTrials gov [Internet] 2013, National Library of Medicine (US), Bethesda (MD), Available from: www.clinicaltrials.gov/ct2/show/NCT01170663.
47. Li J. Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer. ClinicalTrials gov [Internet] 2013, Bethesda (MD), National Library of Medicine (US), Available from: www.clinicaltrials.gov/ct2/show/NCT01512745.
48. Li J., Qin S., Xu J., et al. A randomized, double-blind, multicenter, phase II, three-arm, placebo-control study of apatinib as third-line treatment in patients with metastatic gastric carcinoma. ASCO Meet Abstr 2011, 29(Suppl. (15)):4019. June.
49. Bang Y.J., Kang Y.K., Kang W.K., et al. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs 2011, 29(6):1449-1458. December.
50. Sun W., Powell M., O'Dwyer P.J., Catalano P., Ansari R.H., Benson A.B. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 2010, 28(18):2947-2951. June.
51. Khokhar N.Z., Altman J.K., Platanias L.C. Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies. Curr Opin Oncol 2011, 23(6):578-586. November.
52. Prins M.J., Verhage R.J., Ruurda J.P., ten Kate F.J., van H.R. Over-expression of phosphorylated mammalian target of rapamycin is associated with poor survival in oesophageal adenocarcinoma: a tissue microarray study. J Clin Pathol 2013, 66(3):224-228. March.
53. Doi T., Muro K., Boku N., et al. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol 2010, 28(11):1904-1910. April.
54. Van Cutsem E., Yeh K.H., Bang Y.J., et al. Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1. ASCO Meet Abstr 2012, 30(Suppl. (4)):LBA3. January.
55. Al-Batran S. A Randomized, Double Blind Study Evaluating Paclitaxel with and without RAD001 in Patients with Gastric Carcinoma after Prior Chemotherapy (AIO-STO-0111). ClinicalTrials gov [Internet] 2013, 23 National Library of Medicine (US), Bethesda (MD), March. Available from: www.clinicaltrials.gov/ct2/show/NCT01248403.
56. Gherardi E., Birchmeier W., Birchmeier C., Vande W.G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012, 12(2):89-103. February.
57. Lee J., Seo J.W., Jun H.J., et al. Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep 2011, 25(6):1517-1524. June.
58. Iveson T., Donehower R., Davidenko Iea. Safety and efficacy of ECX plus rilotumumab as first-line treatment for unresectable locally advanced or metastastic gastric and EGJ adenocarcinoma. ESMO Ann Meet 2011, Abstr 6504.
59. Oliner K.S., Tang R., Anderson A., et al. Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer. ASCO Meet Abstr 2012, 30(Suppl. (15)):4005. May.
60. Amgen Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma (RILOMET-1) 2013, March. www clinicaltrialsgov/ct2/show/NCT01697072.
61. Hoffmann-La Roche A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric). ClinicalTrials gov [Internet] 2013, National Library of Medicine (US), Bethesda (MD), March. Available from: www.clinicaltrials.gov/ct2/show/NCT01662869.
62. Kim R., Tan A., Choi M., El-Rayes B.F. Geographic differences in approach to advanced gastric cancer: is there a standard approach?. Crit Rev Oncol Hematol 2013, June.